Pyrazinamide is one of four first-line antibiotics used to treat tuberculosis, however antibiotic susceptibility testing for pyrazinamide is problematic. Resistance to pyrazinamide is primarily driven by genetic variation in pncA, an enzyme that converts pyrazinamide into its active form.
Introduction
Mycobacterium tuberculosis is an evolutionarily ancient human pathogen that is the leading cause of death by infectious disease worldwide 1 . In 2017, tuberculosis was responsible for 1.6 million deaths and 10 million new infections 1 . Tuberculosis control efforts have been hampered by the evolution of resistance to antibiotics, threatening the efficacy of the standard four drug antibiotic regimen consisting of rifampicin, isoniazid, ethambutol, and pyrazinamide 1, 2 .
Pyrazinamide plays a critical role in tuberculosis treatment through its specific action on slowgrowing, "persister" bacteria that often tolerate other drugs due to their reduced metabolism [3] [4] [5] [6] .
This unique activity has been instrumental in shortening the standard treatment duration to six months, substantially increasing the effectiveness of antibiotic therapy 5, 6 . Numerous studies have also found that including pyrazinamide in treatment regimens increases sputumconversion rates in both pan-susceptible and multidrug-resistant (defined as resistant to rifampicin and isoniazid) tuberculosis populations 7 . Due to its unique sterilizing effect and its synergy with new tuberculosis drugs such as bedaquiline, pyrazinamide is also included in most new treatment regimens targeting drug-resistant tuberculosis [8] [9] [10] [11] [12] [13] . Therefore, accurately and rapidly determining whether a clinical isolate is resistant to pyrazinamide is critically important for the treatment of tuberculosis.
The majority of culture-based laboratory methods to determine pyrazinamide resistance are technically challenging, requiring highly-trained technicians. Even then, results are often not reproducible, meaning these methods are rarely employed in low-resource and/or high-burden clinical settings 14 . Even the current gold standard, the Mycobacteria Growth Indicator Tube (MGIT), which is relatively simple to use, can suffer from low precision, with false-resistance rates of 1-68% reported [15] [16] [17] [18] [19] [20] [21] . As the prevalence of multidrug-resistant and extensively drugresistant TB increases, this lack of precision will become more of a problem and hence the WHO is evaluating the efficacy of genetics-based approaches such as line-probe assays or whole genome sequencing for all first-line tuberculosis antibiotics during 2019 22 . 5 fundamentally limits the sensitivity and specificity of heuristic approaches that aim to predict the effectiveness of pyrazinamide based on a catalogue of previously-observed genetic variants 4, 14, 31, 32, 37, 39, 40 .
Genetics-based clinical microbiology for tuberculosis depends on being able to predict or infer the effect of any likely occurring pncA mutation on pyrazinamide susceptibility. Recent studies to identify pyrazinamide-resistance determining mutations have focused on either classifying mutations from previously observed clinical isolates or discovering novel mutations through in vitro/in vivo screening approaches 23, 32, 41, 42 . However, these strategies are constrained, respectively, by the relative paucity of sequenced clinical isolates compared to the number of potential resistance-causing mutations and the lack of laboratory capacity to systematically generate and test mutants. A computational modelling approach could potentially predict the effect of a significant number of missense mutations before they are observed in clinical isolates, allowing clinicians to more rapidly make an informed decision in the face of emerging resistance patterns as well as focusing future fundamental in vitro studies on the most important mutations to investigate.
In this paper, we demonstrate that machine-learning models can robustly and accurately predict the effect of missense amino acid mutations on pyrazinamide susceptibility. The models were trained using a derivation dataset of 291 non-redundant, missense amino acid mutations in PncA collected from pooled MGIT phenotypic studies and a comprehensive in vitro/in vivo pyrazinamide-resistance screen (Methods, Table 1 , S1) 23, 32, 41, 42 . This dataset reflects the clinically observed distribution of mutations across the pncA gene ( Figure 1A) , and consequently, throughout the protein structure. Since the pncA gene is not essential, our hypothesis is that missense mutations can confer resistance by altering the folding, stability or function of the PncA protein. This led us to consider how each mutation perturbs the local chemistry and overall structure of the protein. Hence, we used information about the structural and chemical properties and evolutionary context of the wild-type and mutant amino acids in 6 question as inputs for several different machine-learning models (Methods). The predictions from the best performing model were then re-applied to an aggregated clinical dataset to examine their clinical relevance and also validated against a smaller, independent quantitative dataset of in vitro pyrazinamide minimum inhibitory concentrations (MICs) to determine their capacity to also predict the degree of resistance for specific mutations ( Table 1) . Finally, the model was used to predict the effect of all (1105) non-synonymous substitutions possible from single nucleotide polymorphisms in pncA on the action of pyrazinamide. These data were then used to predict the occurrence of pyrazinamide resistance in a large dataset of 47,769 M. tuberculosis sequences downloaded from public genetic sequence repositories (Table 1) 43, 44 .
This study is a proof of principle for using computational approaches to model and predict antibiotic resistance in other drugs, such as bedaquiline, pretomanid/delamanid, isoniazid, and ethionamide, where some genes implicated in resistance pathways appear to be non-essential. 
Results

Dataset
Structural and evolutionary traits correlate with mutational impact on pyrazinamide susceptibility
Recent studies have implicated synonymous substitutions in altering protein folding and thus function through changes in the rate of translation [46] [47] [48] . This process is mediated through the different availabilities of complementary tRNA in the intracellular milieu 46, 48 . Indeed, Yadon et al found that some synonymous substitutions were enriched in both in vivo and in vitro screens, suggesting that changes in the rate of protein translation offer a bona fide route to pyrazinamide resistance 42 . As previous studies have noted that functional synonymous mutations are enriched for at conserved codons, we tested to see if these variants were similarly enriched at conserved sites in pncA, but we found no significant difference. Given the dearth of isolates harboring sSNPs that have resistant phenotypes, the lack of data on tRNA concentrations in M. tuberculosis and, the lack of any association between resistance-causing sSNPs and conserved codons, we have no information from which to predict the effect of synonymous mutations. Further work to measure pyrazinamide MICs on large numbers of clinical strains is needed, as the effects of these sSNPs may result in sub-MIC shifts in resistance that could be clinically relevant 49 .
We built a preliminary set of 722 non-synonymous substitutions in pncA that had either been observed multiple times in clinical isolates for which antibiotic susceptibility testing data was available or were generated in a high-precision laboratory screening study of pncA resistance variants (Methods). To create a high confidence dataset for model training, we discarded mutations for which there was any uncertainty around whether they conferred resistance (or not), which left us with a final derivation dataset of 291 missense mutations ( mutations across the gene sequence and protein structure (Figure 1A ,C) 14, 31, 32, 39, 42 .
Interestingly, there were a significant number of pncA codons where different mutations associated with either resistance or susceptibility were seen, suggesting that the change in local chemistry introduced by the mutant amino acid is an important factor in determining resistance ( Figure 1A) . The amino acid positions with the highest mutational diversity in the dataset were all residues involved in active site formation or metal binding, suggesting that, consistent with our hypothesis, loss or alteration of these functions is a common mechanism for gaining pyrazinamide resistance. Indeed, previous studies have noted a negative correlation between a mutation's distance from the active site and its tendency to cause resistance ( Figure S1 ) 32, 42, 50 .
Examining the PncA structure also suggested that resistant mutations were more likely to be buried in the protein core, consistent with findings from previous in vitro and in vivo screens (Figure 2A ) 32, 42 . Alterations in the hydrophobic core of a protein are likely to be destabilizing [51] [52] [53] [54] . Indeed, some pyrazinamide-resistant mutations result in reduced production of functional PncA, perhaps due to impaired protein folding/stability 42, 55 . To assess a pncA mutation's impact on the stability of PncA, we employed a meta-predictor that calculates the predicted change in free energy of protein unfolding in silico 56 . This is a fast, heuristic method;
although other more accurate methods exist, these require vastly greater computational resources 57 .
In addition to these chemical and structural properties, we also included information on the evolutionary variation at each position obtained from multiple sequence alignments of related orthologs (Methods). Unsurprisingly, increased conservation at a position was associated with a higher potential of a mutation at that position to confer resistance ( Figure S1 ).
Finally, we applied a recent computational method, called Multivariate Analysis of Protein Polymorphism (MAPP), that quantifies the evolutionary constraints imposed on a given position in a protein 58 . MAPP does this by combining the range of physicochemical amino acid properties observed at a particular position in a multiple sequence alignment with weights generated from the branch lengths of a phylogenetic tree 58 . Resistant mutations had significantly higher MAPP scores, indicating that resistance-conferring mutations in pncA are less conservative in amino acid chemistry and function (Figure 2B , S1).
Machine-learning models accurately predict pyrazinamide resistance
Univariable logistic regression over the derivation dataset revealed that most of the individual predictors were associated with resistant phenotypes (Table S2, Figure 2F ). The MAPP score and solvent accessibility proved to be the most discriminatory individual features.
As PncA can be inactivated through defects in protein folding, reduced stability, distortion of active site geometry, abrogation of metal binding, or some combination of these, we expected a machine-learning approach to be ideally suited to simultaneously consider all these possible mechanisms of PncA inactivation, and hence more accurately predict pyrazinamide resistance/susceptibility.
To evaluate the different models, we randomly divided our derivation dataset mutations (184 resistant, 107 susceptible) into a 70% training set and a 30% testing set, preserving the overall distribution of resistant and susceptible mutations. Models were then trained using repeated 10-fold cross validation (Methods). Since the models output a probability of resistance between 0 and 1, we defined three categories; resistant (R, p<0.4), susceptible (S, p>0.6) and
uncertain (U, 0.4≤p≤0.6) ( Figure S2A) . A model call of uncertain (U) was considered a minor error for the purposes of comparing to binary (R/S) phenotypic data. The models were able to call ~87-99% (183-190) of the mutations in the training set using these thresholds. As expected, drops in performance (as measured by area under the ROC curve) were observed for all models when applied to the independent testing set, however the 95% bootstrap confidence intervals for training and testing overlapped for all three methods (Figure 3 , Table S3 ). The neural network (NN) model had the highest diagnostic odds ratio (119), followed by logistic regression (LR, 45) and then the support vector machine (SVM, 24, Figure 3 ). As the best performing model, the predictions from the neural network model were used for all further analyses.
Analysis of model errors on the derivation set
Clinical diagnostic errors for antibiotic resistance are categorized into three classes: very major errors, which represent truly resistant isolates that are called susceptible, major errors (true susceptible cases called resistant), and minor errors, which are not called by the method being tested but are determined as resistant or susceptible by the reference method 59 .
Collectively, the three models made 107 incorrect calls (28 very major errors, 29 major errors, and 50 minor errors); however, only 14 of these were shared between all three models (8 very major errors and 6 major errors, Figure 4A , Table S4 ). The best performing model (neural network) had a sensitivity of 93% (89-97%), a specificity of 86% (79-93%), and a positive predictive value of 94% (91-97%) with minor errors considered equivalent to major and very major errors where appropriate (Table S3 ).
Although the mutations responsible for the very major errors (predicted susceptible, phenotypically resistant) of the neural network model were dispersed throughout the protein structure, most (10/11) were surface exposed ( Figure 4B ). All these mutations were predicted to either not affect or slightly increase the stability of PncA, suggesting these errors may be due to inaccuracies in the predicted free energy change of unfolding ( Figure S2 ). Major errors (predicted resistant, phenotypically susceptible) were typically driven by overestimation of a mutation's potential to effect PncA structure or function. Mapping the mutations responsible for these major errors onto the sequence and structure revealed one cluster near the active site and the coiled turn between the a-1 and a-2 helix (residues 15, 21, 23, 131, and 133) ( Figure   4B , C). Major errors appear to be caused in part by a combination of overestimation of the MAPP score at invariant positions that are near the active site or buried in the protein core.
Interestingly, several major errors occurred in a region of the active site termed the "oxyanion hole" (residues 131-138) which coordinates the carbonyl group of pyrazinamide in the active site 50 . The effects of mutations that lie in this region could be over-estimated due to their proximity to the active site and relatively lower solvent exposure. As the interaction between the oxyanion hole and pyrazinamide is mediated by the peptide backbone, and is therefore sidechain-independent, there is likely to be less stringent selection of the residues at these positions as long as the overall peptide backbone structure is maintained. Interestingly however,
Gly132 and Ala134 are invariant in the alignment used to generate the MAPP score, which would suggest that these sites are under strong selective pressures. It has been shown previously that specific residues are favored in the positions surrounding cis peptide bonds, so 15 future work could attempt to model the mutations occurring in this functional region more specifically 60 .
Minor 
Neural network predictions generalize to a large clinical dataset
To assess the generalizability of our best model, the neural network, we applied its predictions to a clinical dataset of 2,292 pncA gene sequences with MGIT antibiotic susceptibility results (Table 1) , each representing a unique isolate collated from published studies of clinical isolates 23, 32, 41, 42 . In addition to the clinical isolates that were used to build the derivation dataset, this dataset also included 500 isolates with mutations that were only observed once or isolates with mutations whose phenotype appeared to vary between isolates tested. Thus, this dataset includes noisier phenotypic data that encapsulates both the uncertain phenotypes of some mutations and the real-world variability of culture-based phenotypic methods for pyrazinamide susceptibility testing. As the models were trained on high-confidence phenotypes derived from pooled MGIT phenotypes for each mutation, the 204 mutations used in the training set represented 1,096 isolates (48%) of the clinical dataset, while 1,196 isolates (52% of the clinical dataset) harbored mutations that were not used in model training. Predicting Figure 5A) . 68 .1% (287/421) of U calls made by the model were associated with resistance, which suggests that clinically a U call could be interpreted as possible pyrazinamide resistance contingent upon further testing (Figure 5A) . (Figure 5B) . Overall, the model more accurately (as assessed by the diagnostic odds ratio) predicted the average phenotypes of mutations than the individual MGIT phenotypes of clinical isolates. The model still made 11 very major errors on the average phenotypes; however, some of these errors may be due to errors in MGIT antibiotic susceptibility testing. Alternatively, these errors could result from resistance that is determined by factors upstream of protein folding and function and is therefore outside the scope of our model. These results collectively suggest that the model predictions could be used to confirm MGIT susceptibility test results, with a discordant result suggesting that culture-based testing should be repeated.
Comparison of model predictions with pyrazinamide minimum inhibitory concentrations in vitro
Since it is difficult to assess how much of the discordance in the previous section can be attributed to either error in the measured clinical phenotype or deficiencies in our model, we compared its predictions to minimum inhibitory concentration (MIC) data taken from a small but high-quality dataset of 71 M. tuberculosis isolates (59 unique missense mutations, quantitative dataset, isolates in total) that were not in either the derivation or clinical datasets ( Table S6) . One of these errors is likely due to a MGIT testing error, as the same mutation (Gly97Asp) is observed in another resistant isolate and has been classified as conferring resistance in other studies (Table S1 ). Interestingly, of the seven isolates with mutations previously cataloged as susceptible (Table S1 ), four had MICs that were above the R/S cutoff of 100 µg/mL, highlighting the variability in MIC determination for pyrazinamide using MGIT. Out of the 18 isolates with mutations that lacked previously classified R/S phenotypes, 10 harbored mutations with disputed effects, and 8 harbored mutations that had previously lacked sufficient evidence to be classified. In addition, several samples with large deletions in pncA were also observed; these strains had extremely high (>900 µg/mL) MICs, which is consistent with the loss of functional PncA protein (Table S6 ). These data, taken together with the results for isolates harboring insertions/deletions in the study by the CRyPTIC Consortium et al, confirm it could be reasonable to assume that nearly all large insertion/deletion mutations and frameshifts in pncA confer resistance to pyrazinamide 23 .
Predicting the effect of all possible non-synonymous pncA mutations on pyrazinamide susceptibility
Since trained machine learning models require very little computational resource, we applied our model to the set of missense mutations resulting from every possible nonsynonymous single nucleotide polymorphism (SNP) in pncA (coding for 1,105 unique amino acid changes, 814 previously unclassified missense mutations), thereby estimating the probability that each mutation confers pyrazinamide resistance (Table S5) . Overall, 22% (244) of missense mutations were predicted to confer resistance, while 63% (691) were predicted to have no effect on the action of pyrazinamide and the remaining 14% (158) were predicted to have an uncertain effect. Interestingly, the proportion of predicted resistant mutations from all possible non-synonymous SNPs was much lower than that in the derivation set (22% versus 63% respectively). This may be due to an increased likelihood of sequencing pyrazinamideresistant clinical isolates, leading to an over-representation of resistance-conferring mutations in our derivation dataset as opposed to susceptible ones. This estimate is also more consistent with the proportion of resistant mutations identified in the Yadon et al screen (31%) 42 . As more unselected studies of whole genome sequencing are conducted, we expect this bias to unwind and consequently more susceptible mutations will be found for most established drugs.
Alternatively, it could be caused by a global underestimation of resistance by our model, which To try and get an understanding of how these predictions could improve our capacity to identify resistant mutations in pncA, we queried a bacterial index of the European Nucleotide Archive (ENA) to identify all single nucleotide polymorphisms (SNPs) coding for missense mutations in the M. tuberculosis pncA coding sequence (Table S5) 43 . We found 37,560 sequences classified as M. tuberculosis, with 4,102 strains harboring single missense mutations in PncA (Methods). We supplemented this ENA dataset with the pncA sequences collected by CRyPTIC et al 23 as these sequences were not deposited when the index of the ENA was built, bringing the total number of strains with single missense mutations to 6,193 (47,769 total sequences, prevalence dataset, Table 1 ). We are using this dataset as the largest available sample of the genetic diversity in PncA existing in clinical infections; this is almost certainly biased to some degree due to oversampling of outbreak strains and other factors, however, until very large unselected clinical datasets are collected, it is the best dataset available.
Out of the 480 unique missense mutations observed in the prevalence dataset, 237 were observed in at least two lineages. After applying our predictions, we found that homoplastic (observed in at least two lineages) missense mutations in PncA were associated with resistance (odds ratio = 4.4, p<0.0001). 327 (68%) mutations were observed 10 or fewer times and 111
(23%) only once, highlighting again the need for approaches capable of predicting the effect of rare missense mutations. We classified the prevalence dataset using a published heuristic catalog 45 , supplemented with our resistant and susceptible model predictions, to quantify how much our machine learning model improves our capacity to screen for potential pyrazinamide resistance using whole genome sequencing. While the heuristic catalog alone was able to classify 4,022 strains (73%, 291 mutations), our model classified an additional 983 strains (17%, 47 mutations), allowing us to provisionally classify 90% of the strains with missense mutations in the prevalence dataset.
Discussion
De novo prediction of 814 pncA mutations' effects on pyrazinamide resistance constitutes a significant step forward in our ability to predict pyrazinamide resistance from genetics and a proof of concept for using structural approaches to infer the effects of pncA SNPs on pyrazinamide resistance. While improvements to the model are necessary to achieve the sensitivity and specificity required for routine clinical use, this work increases our ability to classify rare resistance mutations, thereby potentially increasing the capability of whole genome sequencing based diagnostic susceptibility testing to respond to emerging and rare resistance patterns, as well as prioritizing rare resistance mutations for in vitro validation. Additionally, improving the classification of susceptible pncA mutations will allow us to begin to disentangle the involvement of other genes in pyrazinamide resistance, including determining the effect of mutations in other pyrazinamide resistance-associated genes such as panD and rpsA.
There are two principal limitations of this approach: (1) since the training set uses a binary resistant/susceptible phenotype, the models can only predict whether a mutation confers high-level resistance (>100 µg/mL) or not and (2) it can only make predictions for missense mutations in the coding sequence of pncA. It is known that genetic variation can lead to small changes in MIC for pyrazinamide and other first-line antitubercular compounds and that, whilst these may not change the binary phenotype, they do affect clinical outcome 49, 61 . Models that predict the change in MIC due to genetic variation would be very helpful and interesting, however, until very large datasets of pyrazinamide MICs and their associated genomes become available, we must be content with predicting binary phenotypes. In addition, while we have shown that missense mutations represent most (60.5%) of the possible resistant genetic variants in pncA, insertions/deletions and nonsense mutations (7.9%) must also be considered, as they are generally associated with resistance. Likewise, promoter mutations that result in reduced transcription of pncA will likely also lead to resistance. While no synonymous mutation has yet been observed to cause clinical pyrazinamide resistance, the possibility remains that a synonymous mutation could have an effect on RNA stability, ribosomal stalling, or codon usage and confer resistance. Indeed, Yadon et al do pick up 18 sSNPs that are enriched both in vivo and in vitro in their pyrazinamide resistance screens 42 . The model also does not take into account the introduction of protease cleavage sites or other processing abnormalities. Finally, while most pyrazinamide resistance is caused by mutations in pncA, recent studies have also implicated other genes, notably rpsA, panD, and the putative efflux pumps Rv0191, Rv3756c, Rv3008, and Rv1667c in pyrazinamide resistance 4, [25] [26] [27] [28] [29] [30] [31] . Further research is needed to determine if mutations in these genes can be reliably inferred to confer pyrazinamide resistance.
Several predictive features used in the model could be improved upon in future work.
The MAPP score relies on the maintenance of function between diverse homologs to determine the evolutionary constraints on each position in a protein. While we selected sequences that contained the residues involved in active site formation and metal binding, we did not experimentally confirm pyrazinamide conversion by each homolog. Additionally, the in silico method that we employed to estimate each mutation's effect on protein stability could be improved by comparison and calibration with in vitro biochemical data. Finally, as the active site of PncA is formed in part by a cis peptide bond between Ile133 and Ala134, more detailed modeling of the evolutionary constraints at this site could more accurately assess the functional impact of a mutation at these positions. Despite the fact that most features we investigated were associated with pyrazinamide resistance, not all were retained as independent predictors in our final logistic regression model. The change in hydropathy and sidechain volume as well as the Rogov score are all likely encapsulated by the MAPP score, as this takes into account the wildtype and mutant amino acids in its calculation.
The accuracy of model predictions based on structural features suggests that the underlying hypothesis of predicting pyrazinamide resistance based on predicted PncA function is valid. Mapping the potential of each position to harbor a predicted or bona fide resistance mutation onto the structure reveals that many resistance-prone positions are associated with the active site or metal binding, as noted previously (Figure 1C) . Interestingly, however, most of the other resistance-prone positions are involved in packing interactions between secondary structure elements in PncA, supporting the assertion that a major mechanism of pyrazinamide resistance is loss of protein stability. All susceptibility-prone positions are highly solventexposed and many are on flexible loops, consistent with our expectation that these regions experience lower selective pressures and have a lower/negligible effect on PncA stability and function. The effect of perturbing the protein core appears to be more dependent on the specific amino acid chemistries involved, as many codons harbor nearly equal numbers of resistant and susceptible mutations, which is consistent with the ability of a conservative, hydrophobic mutation to be tolerated in a region that relies on non-specific, volume-mediated packing driven by the hydrophobic effect.
One major question that remains is whether the mutations not called by the model ( (Figure S2) . The MAPP score has been shown to be capable of delineating mutations that have mild and severely deleterious effects in other genes, suggesting that mutations with intermediate MAPP scores may indeed be intermediate in effect 58 . In addition, some of the mutations that are called U appear to not be reproducible when experimentally tested using the chosen gold-standard culture-based method, MGIT, supporting the possibility of an intermediate class (Figure 5B) . One previous study has shown associations between reductions in PncA stability/function in vitro and outcomes in infected mice, but more work is necessary to fully understand whether this relationship extends to clinical outcomes in patients 42 . While mutations have historically been classified using a binary system, this study supports the view of mutations as conferring a spectrum of resistance. This is evidenced by the variable effects on MIC for some of the mutations investigated in this study, three of which range from susceptible to above the MGIT breakpoint for pyrazinamide (100 µg/mL, Table S6 ).
Future approaches could examine either probabilistic modelling or multi-class classification to attempt to encapsulate the uncertainty in phenotype associated with certain pncA mutations.
Additionally, mutations could also be weighted in training by their relative prevalence in the ENA, which would prioritize accuracy for abundant mutations. However, this may result in bias toward highly sequenced variants that are a part of outbreak strains.
Predictions made by this model could potentially provide clinicians with an initial estimate of pyrazinamide susceptibility after a novel mutation is observed but before traditional phenotypic testing has been completed. Given the latter can take weeks or even months, this could help guide initial therapy and further antibiotic susceptibility testing. In addition, the putative classification of additional pncA mutations potentially enables genetic variants conferring pyrazinamide resistance that do not involve the pncA gene to be discovered. The identification of pyrazinamide-susceptible mutations is also crucial, as it has been suggested that any non-synonymous mutation in pncA that is not cataloged as susceptible confers resistance, an incorrect assumption that would lead to overprediction of pyrazinamide resistance 62 .
This study constitutes a proof-of-concept for the computational prediction of pyrazinamide resistance, a critically important drug in the treatment of tuberculosis. However, this approach is not limited to pncA but should in theory be extensible to any pro-drug system where the converting enzyme is non-essential, such as delaminid, protaminid, or ethionamide as well as to pro-drug systems outside of M. tuberculosis. Interestingly, a recent study has highlighted similar trends in the features used in this study for resistance-conferring mutations in katG (isoniazid), rpoB (rifampicin), and alr (D-cycloserine), suggesting that this approach may even be applicable to non-prodrug systems 63 . One promising area for future work is in the tuberculosis drug bedaquiline, where resistance is caused in part by mutations in a transcriptional repressor (Rv0678) that cause loss of DNA binding and upregulation of efflux 26 pumps 64, 65 . Rv0678 has shown a high degree of mutational promiscuity in published sequencing studies, which would highlight the value of a computational approach [66] [67] [68] [69] [70] . The ability of this approach to identify the major mechanisms of resistance to pyrazinamide highlights the need for continued basic research to determine the structures of other bacterial proteins implicated in antibiotic resistance. Additionally, the efficacy of this approach highlights the value of including evolutionary constraints for prediction of mutational effects. Further understanding of the effect of pncA mutations also increases the ability of whole genome sequencing approaches to move to the forefront of global tuberculosis control efforts. 
Methods
Mutation phenotype thresholds
Mutations included in the derivation (training and testing) dataset were selected from four large studies/reviews that included phenotypic diagnostic susceptibility testing of clinical isolates for pyrazinamide and one in vitro/in vivo phenotypic screening study 23, 32, 41, 42, 45 . Briefly, phenotypes for strains with single missense mutations in pncA from the four studies of clinical isolates were aggregated by mutation, tallying the results of the phenotypic testing. Mutations that were resistant or susceptible at least 75% of the time and that had been phenotyped at least 4 times were included as derivation phenotypes. Additionally, mutations that had been phenotyped at least twice with no discrepancies were also included. These mutations were then cross-referenced and supplemented with mutations from Yadon et al. that were either enriched (resistant) or depleted (susceptible) in both the in vitro and in vivo screens performed in that study 42 . Mutations that had conflicting clinical and laboratory phenotypes (n=2) were removed from the derivation dataset. Mutations that were only present in either clinical isolates or in vitro isolates but that met the criteria for inclusion from that set were included. This led to a final total of 291 mutations with high-confidence phenotypes of which 184 were resistant and 107 were susceptible to pyrazinamide.
In silico structural measurements
The change in mass, volume, charge, hydrophobicity, distance from the Fe 2+ ion and pyrazinamide molecule, solvent accessibility, MAPP score, Rogov score, degree of hydrogen bonding, and predicted change in the free energy of protein unfolding were determined for each mutation. Hydrophobicity was estimated using the Kyte-Doolittle scale. Distances were calculated as the minimum distance between each residue and the Fe 2+ ion or pyrazinamide molecule using UCSF Chimera. Solvent accessibility and predicted number of hydrogen bonds were calculated in UCSF Chimera. In silico calculation of the change in free energy of protein unfolding was calculated using a meta-predictor as described in Broom et al 56 . The MAPP score was calculated using software available at (http://mendel.stanford.edu/SidowLab/downloads/MAPP/index.html) using related orthologs.
Statistical modelling procedures
Logistic regression, support vector machines with radial kernels, and multi-layer perceptron neural networks were implemented using the R caret package. Briefly, 70% of the derivation dataset was randomly selected (maintaining the ratio of resistant to susceptible phenotypes) as a training set and 30% was reserved as a test set. All three model types were trained using repeated (n=10) 10-fold cross validation with class weights to compensate for the class imbalance. Model performance was evaluated by the area under the receiver-operating characteristic curve. After model selection for each method, generalizability was determined using an independent test set. The final model was selected by calculating the diagnostic odds ratio for each method over the entire derivation set. In order to select the variables used for logistic regression, backwards stepwise elimination (exit p=0.15) was performed on the entire derivation dataset to select the main effects and then interactions between the significant terms were manually investigated, retaining any with heterogeneity p<0.05. Two additional weak interactions (between the protein destabilization factor and either number of hydrogen bonds (p=0.073) or solvent accessibility (p=0.054)) were not included in the final model. The final logistic regression model was trained using the identified main effects with the two significant interactions on the training set using repeated (n=10) 10-fold cross validation to select hyperparameters before being applied to the test set. The training set along with all relevant R code is publicly-available (https://github.com/carterjosh/PZA-machine-learner). This allows the reader to either load the three machine-learning models described, or to repeat the training process thereby creating their own models.
Prevalence Dataset Construction
The European Nucleotide Archive was queried using pygsi and the H37Rv reference sequence for pncA with 10 nucleotides padded on either side 43, 44 . This allowed for sequence search of all possible single nucleotide mutations in pncA that have been deposited in the ENA.
In total, 38,440 pncA sequences classified as originating from Mycobacterium tuberculosis were extracted. These were combined with pncA sequences determined by the CRyPTIC Consortium et al and filtered for single missense mutations to form the final prevalence dataset 23 .
Pyrazinamide minimum inhibitory concentration determination
Isolates used for MIC determination came from two sources, the EXIT-RIF study and US All MICs were determined using the non-radiometric BACTEC MGIT 960 method (BD Diagnostic Systems, NJ, USA) with manufactured supplied pyrazinamide medium/supplement
